| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/IMR.12233 |
| P698 | PubMed publication ID | 25510276 |
| P50 | author | Michele Moschetta | Q96028446 |
| Yawara Kawano | Q84529928 | ||
| Siobhan V Glavey | Q85282138 | ||
| Salomon Manier | Q88032950 | ||
| Irene Ghobrial | Q88032966 | ||
| Kenneth C. Anderson | Q28421846 | ||
| Aldo M Roccaro | Q40001639 | ||
| P2093 | author name string | Güllü T Görgün | |
| P2860 | cites work | Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB | Q22009950 |
| Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow | Q24291392 | ||
| Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death | Q24293504 | ||
| Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 | Q24317429 | ||
| VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche | Q24600542 | ||
| Multiple myeloma | Q24655964 | ||
| Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro | Q24675778 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma | Q28236113 | ||
| A severe combined immunodeficiency mutation in the mouse | Q28274531 | ||
| Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications | Q40339607 | ||
| Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma | Q40342424 | ||
| Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. | Q40412896 | ||
| Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. | Q40473651 | ||
| CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative | Q40591372 | ||
| Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines | Q40608301 | ||
| Natural Killer Cell Frequency and Serum Cytokine Levels in Monoclonal Gammopathies: Correlation of Bone Marrow Granular Lymphocytes to Prognosis | Q40910875 | ||
| Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. | Q41839288 | ||
| Dysfunctional T regulatory cells in multiple myeloma | Q41877240 | ||
| Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma | Q42014659 | ||
| Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients | Q42742001 | ||
| PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine | Q42839507 | ||
| Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | Q43648034 | ||
| Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity | Q43883711 | ||
| Endothelial cells in the bone marrow of patients with multiple myeloma | Q44509638 | ||
| BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. | Q44542640 | ||
| Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma | Q44598895 | ||
| Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide | Q45182740 | ||
| Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug | Q45851460 | ||
| Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. | Q45966936 | ||
| Pathogenesis of myeloma bone disease | Q46224909 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells | Q46882677 | ||
| A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | Q46952812 | ||
| Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. | Q47637765 | ||
| Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice | Q48086223 | ||
| Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth | Q50539541 | ||
| Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma | Q50621370 | ||
| ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells | Q50935651 | ||
| Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma | Q51738850 | ||
| Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma | Q51950783 | ||
| In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma | Q51985543 | ||
| Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells | Q53100223 | ||
| Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma | Q53377096 | ||
| Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. | Q55043619 | ||
| CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden | Q56461588 | ||
| Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model | Q56899357 | ||
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host | Q57054792 | ||
| Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer | Q57571531 | ||
| Expression of VEGF and its receptors by myeloma cells | Q58050891 | ||
| Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse | Q58211903 | ||
| Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma | Q59245171 | ||
| Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function | Q28510096 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 | ||
| Angiogenesis in life, disease and medicine | Q29614539 | ||
| Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 | ||
| CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. | Q30487339 | ||
| Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. | Q30490975 | ||
| Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10 | Q30763343 | ||
| Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells | Q33385308 | ||
| Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells | Q33528090 | ||
| TPL2 kinase regulates the inflammatory milieu of the myeloma niche | Q33714724 | ||
| Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells | Q33919954 | ||
| Engineered nanomedicine for myeloma and bone microenvironment targeting. | Q33926003 | ||
| A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib | Q33976734 | ||
| Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management | Q34111475 | ||
| Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy | Q34263870 | ||
| Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent | Q34292398 | ||
| Multiple myeloma macrophages: pivotal players in the tumor microenvironment. | Q34329152 | ||
| Induction of angiogenesis during the transition from hyperplasia to neoplasia | Q34413571 | ||
| Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. | Q34447864 | ||
| Novel therapies targeting the myeloma cell and its bone marrow microenvironment | Q34461557 | ||
| Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells | Q34485147 | ||
| Immune surveillance of tumors | Q34579196 | ||
| Hypoxia-inducible factors, stem cells, and cancer | Q34625782 | ||
| Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model | Q35345202 | ||
| The role of Notch in tumorigenesis: oncogene or tumour suppressor? | Q35564593 | ||
| Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo | Q35642745 | ||
| The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma | Q35739463 | ||
| Advances in biology of multiple myeloma: clinical applications | Q35748276 | ||
| Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features | Q36057606 | ||
| Tumour-associated macrophages and cancer | Q38115023 | ||
| Macrophages in multiple myeloma | Q38173982 | ||
| Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease | Q38306073 | ||
| Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. | Q39129256 | ||
| Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma | Q39308923 | ||
| Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. | Q39402566 | ||
| Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade | Q39549859 | ||
| Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression | Q39550131 | ||
| Angiogenesis and Multiple Myeloma | Q39696428 | ||
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody | Q39705098 | ||
| Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma | Q39830418 | ||
| Induction of angiogenesis by normal and malignant plasma cells. | Q39870744 | ||
| Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. | Q39901596 | ||
| The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. | Q39916867 | ||
| Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity | Q40013431 | ||
| Myeloma as a model for the process of metastasis: implications for therapy | Q36079800 | ||
| Enhancement of clonogenicity of human multiple myeloma by dendritic cells | Q36082990 | ||
| Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells | Q36092102 | ||
| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 | ||
| Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma | Q36206430 | ||
| The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma | Q36324979 | ||
| In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. | Q36375533 | ||
| MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma | Q36446189 | ||
| Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo | Q36478430 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. | Q36498366 | ||
| Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma | Q36641621 | ||
| Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. | Q36718300 | ||
| BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. | Q36733492 | ||
| Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans | Q36761567 | ||
| Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells | Q36839509 | ||
| PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma | Q36839558 | ||
| Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | Q36889961 | ||
| Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities | Q36893780 | ||
| Immunodeficiency and immunotherapy in multiple myeloma | Q36904977 | ||
| The tumor microenvironment and its role in promoting tumor growth | Q36946019 | ||
| A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. | Q37006834 | ||
| HIF-1alpha determines the metastatic potential of gastric cancer cells | Q37123481 | ||
| Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. | Q37207049 | ||
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma | Q37271048 | ||
| Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis | Q37398320 | ||
| Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma | Q37478912 | ||
| Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. | Q37535244 | ||
| Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer | Q37602926 | ||
| Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease | Q37630599 | ||
| Pathogenesis and management of myeloma bone disease | Q37810077 | ||
| Angiogenesis and Vasculogenesis in Multiple Myeloma: Role of Inflammatory Cells | Q37867560 | ||
| The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. | Q37884379 | ||
| Antiangiogenic Therapeutic Approaches in Multiple Myeloma | Q38025194 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 160-172 | |
| P577 | publication date | 2015-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Immunological Reviews | Q15724582 |
| P1476 | title | Targeting the bone marrow microenvironment in multiple myeloma | |
| P478 | volume | 263 |
| Q57215522 | 3d Tissue Engineered In Vitro Models Of Cancer In Bone |
| Q57045114 | A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma |
| Q45761043 | A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries |
| Q91636854 | Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options |
| Q39136762 | Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression |
| Q38736038 | Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. |
| Q38718211 | Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. |
| Q92526755 | Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients |
| Q89883725 | Bioactive Compounds from Abelmoschus manihot L. Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment |
| Q88109417 | Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression |
| Q90249628 | Bone Marrow Senescence and the Microenvironment of Hematological Malignancies |
| Q50182712 | Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. |
| Q92812162 | Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma |
| Q90468255 | Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients |
| Q89834625 | Bortezomib Treatment Modulates Autophagy in Multiple Myeloma |
| Q52721814 | Bufalin induces DNA damage response under hypoxic condition in myeloma cells. |
| Q37694678 | CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma |
| Q98281077 | Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges |
| Q91743634 | Circulating microRNAs and Their Role in Multiple Myeloma |
| Q38765278 | Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. |
| Q28066890 | Development of Novel Immunotherapies for Multiple Myeloma |
| Q61797911 | Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation |
| Q93047768 | Editorial: Immunotherapy in Multiple Myeloma |
| Q36545216 | Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation |
| Q41370609 | Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma |
| Q64088142 | Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease |
| Q39530606 | Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma. |
| Q89983797 | Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis |
| Q47913337 | Evolutionary biology of high-risk multiple myeloma |
| Q96134363 | Expression and pathogenesis of VCAM-1 and VLA-4 cytokines in multiple myeloma |
| Q38932298 | Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche |
| Q52321084 | HIF-2α-ILK Is Involved in Mesenchymal Stromal Cell Angiogenesis in Multiple Myeloma Under Hypoxic Conditions |
| Q90708999 | Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients |
| Q92027921 | High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment |
| Q87789752 | Hypoxia-inducible KDM3A addiction in multiple myeloma |
| Q33574203 | IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts. |
| Q38708402 | Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies |
| Q89529544 | Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy |
| Q64062300 | Increased expression of miR-27 predicts poor prognosis and promotes tumorigenesis in human multiple myeloma |
| Q45756098 | Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. |
| Q55642634 | Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy. |
| Q40856384 | Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma |
| Q47158965 | Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells |
| Q99629101 | Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib |
| Q99549191 | Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q37469859 | Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma. |
| Q38979865 | MGUS to myeloma: a mysterious gammopathy of underexplored significance |
| Q91896921 | Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma |
| Q28073613 | Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment |
| Q90188315 | Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13 |
| Q53694850 | Metabolic Features of Multiple Myeloma. |
| Q26765477 | MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment |
| Q60909519 | Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update |
| Q90241569 | Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma |
| Q90466676 | Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance |
| Q102388789 | Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment |
| Q36725401 | Multiple myeloma in the marrow: pathogenesis and treatments. |
| Q38821941 | Myeloid-derived suppressor cells: The green light for myeloma immune escape. |
| Q52559684 | Nanotherapeutics for multiple myeloma |
| Q37101382 | Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. |
| Q36043066 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study |
| Q37694101 | Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway. |
| Q55025408 | Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. |
| Q58790080 | Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 |
| Q35607266 | Pathogenesis beyond the cancer clone(s) in multiple myeloma |
| Q52560290 | Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy |
| Q37687419 | Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells |
| Q33443411 | Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma |
| Q48361512 | Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. |
| Q92124987 | Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model |
| Q26744596 | Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells |
| Q58553865 | Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity |
| Q37641801 | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. |
| Q26774440 | Spotlight on ixazomib: potential in the treatment of multiple myeloma |
| Q47855599 | Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors |
| Q40321710 | T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow. |
| Q90196934 | TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma |
| Q58790069 | Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy |
| Q57792135 | Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma |
| Q92382947 | Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling |
| Q38748203 | Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q50114615 | The bone-marrow niche in MDS and MGUS: implications for AML and MM. |
| Q41825014 | The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. |
| Q38494968 | The road to cure in multiple myeloma starts with smoldering disease |
| Q41371363 | The role of the CCN family of proteins in blood cancers |
| Q47135094 | The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma: An 18-year follow-up case report |
| Q57172251 | Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease |
| Q38815409 | Vision Statement for Multiple Myeloma: Future Directions |
| Q90259195 | Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression |
| Q34729522 | When cancer and immunology meet |
| Q36905755 | Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis |
| Q57298079 | YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells |
Search more.